Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNγ-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion

Leukemia

Volumn 19, Issue 1, 2005, Pages 83-90

  Kloosterboer, F M ^a   van Luxemburg Heijs, S A P ^a   van Soest, R A ^a   van Egmond, H M ^a   Barbui, A M ^b   Strijbosch, M P W ^a   Willemze, R ^a   Falkenburg, J H F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Donor lymphocyte infusion; Minor histocompatibility antigen; T cell cloning

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CANCER REGRESSION; CASE REPORT; CELL CLONING; CELL ISOLATION; CELL STIMULATION; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKEMIA; LEUKEMIA RELAPSE; LYMPHOCYTE TRANSFUSION; MULTIPLE MYELOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 11844255367     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403572     Document Type: Article

References (28)

1. Falkenburg JH, van de Corput, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol 2003; 31: 743-751.
2. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, Van Der Hoorn MA et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA- 2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742-2747.
3. Mutis T, Goulmy E. Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin Hematol 2002; 39: 23-31.
4. Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003; 17: 153-162.
5. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998; 279 1054-1057.
6. den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268: 1476-1480.
7. Spierings E, Brickner AG, Caldwell JA, Zegveld S, Tatsis N, Blokland E et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood 2003; 102: 621-629.
8. Brickner AG, Warren EH, Caldwell JA, Akatsuka Y, Golovina TN, Zarling AL et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med 2001; 193: 195-206.
9. Vogt MH, de Paus RA, Voogt PJ, Willemze R, Falkenburg JH. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood 2000; 95: 1100-1105.
10. Wang W, Meadows LR, den Haan JM, Sherman NE, Chen Y, Blokland E et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269: 1588-1590.
11. Vogt MH, Goulmy E, Kloosterboer FM, Blokland E, de Paus RA, Willemze R et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood 2000; 96: 3126-3132.
12. Vogt MH, van den Muijsenberg JW, Goulmy E, Spierings E, Kluck P, Kester MG et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002; 99: 3027-3032.
13. Akatsuka Y, Nishida T, Kondo E, Miyazaki M, Taji H, Iida H et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med 2003; 197: 1489-1500.
14. Nishida T, Akatsuka Y, Morishima Y, Hamajima N, Tsujimura K, Kuzushima K et al. Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant. Br J Haematol 2004; 124: 629-635.
15. Korngold R, Wettstein PJ. Immunodominance in the graft-vs host disease T cell response to minor histocompatibility antigens. J Immunol 1990; 145: 4079-4088.
16. Perreault C, Roy DC, Fortin C. Immunodominant minor histocompatibility antigens: the major ones. Immunol Today 1998; 19: 69-74.
17. Wettstein PJ, Bailey DW. Immunodominance in the immune response to 'multiple' histocompatibility antigens. Immunogenetics 1982; 16: 47-58.
18. Choi EY, Yoshimura Y, Christianson GJ, Sproule TJ, Malarkannan S, Shastri N et al. Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility antigen dominates over all others. J Immunol 2001; 166: 4370-4379.
19. van Els CA, D'Amaro J, Pool J, Blokland E, Bakker A, van Elsen PJ et al. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics 1992; 35: 161-165.
20. Rufer N, Wolpert E, Helg C, Tiercy JM, Gratwohl A, Chapuis B et al. HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation. Transplantation 1998; 66: 910-916.
21. Kloosterboer FM, Luxemburg-Heijs SAP, Soest RA, Barbui AM, Van Egmond HM, Strijbosch MPW et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia 2004; 18: 798-808.
22. Faber LM, Luxemburg-Heijs SA, Veenhof WF, Willemze R, Falkenburg JH. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995; 86: 2821-2828.
23. Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol 2000; 165: 6229-6234.
24. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995; 42: 455-500.
25. Faber LM, Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992; 176: 1283-1289.
26. Smit WM, Rijnbeek M, van Bergen CA, Fibbe WE, Willemze R, Falkenburg JH. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 1998; 95: 10152-10157.
27. Van Der Hoorn MA, Luxemburg-Heijs SA, van Bergen CA, Bongaerts R, Willemze R, Falkenburg JH. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia. Methods 2003; 31: 113-119.
28. Heemskerk MH, de Paus RA, Lurvink EG, Koning F, Mulder A, Willemze R et al. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci USA 2001; 98: 6806-6811.